Harry Penner

Harry H.
Penner founded Nascent BioSciences Inc. in 2001, where he worked as Chairman & Chief Executive Officer, Immedica Pharma US, Inc. in 2003, where he worked as Director, QCDx LLC in 2017, where he worked as Chairman, Melinta Subsidiary Corp.
in 2000, where he worked as Director from 2000 to 2009, and New Haven Pharmaceuticals, Inc. in 2008, where he is working as Executive Chairman from 2012.
Mr. Penner also founded Prevention Pharmaceuticals, Inc., where he is working as Executive Chairman from 2012, Affinimark Technologies, Inc., where he worked as Chief Executive Officer & Director, RHEI Pharmaceuticals, Inc., where he worked as Chairman, Virscio, Inc., where he worked as Chairman, and Omax Health, Inc., where he is working as Director.
Mr. Penner also currently works at Nascent BioScience LLC, as Chairman & Chief Executive Officer from 2001, Celldex Therapeutics, Inc., as Chairman from 2025, MAKScientific LLC, as Director, CaroGen Corp., as Director, Neurovail, Inc., as Director, and Aria Neurosciences, Inc., as Director.
Mr. Penner also formerly worked at Neurogen Corp., as Vice Chairman, President & Chief Executive Officer from 1999 to 2001, Celldex Therapeutics, Inc. (Old), as Chairman, Connecticut Technology Council, as Chairman, Connecticut Board of Governors for Higher Education, as Chairman, Connecticut United for Research Excellence, Inc., as Co-Chairman, AVANT Immunotherapeutics, Inc., as Director from 1997 to 2008, Genaissance Pharmaceuticals, Inc., as Director, Altus Pharmaceuticals, Inc., as Lead Director from 2006 to 2009, Ikonisys, Inc., as Director, Connecticut Business & Industry Association, as Director, Novo Nordisk A, as Executive Vice President from 1988 to 1993, and Novo Nordisk North America, Inc., as President & EVP-North America from 1988 to 1993.
Mr. Penner received his undergraduate degree from the University of Virginia, graduate degree from Fordham University, and graduate degree from New York University.